Johnson & Johnson (JNJ) 99.88 $JNJ
Millennials Are Investing More in Stocks Than You May Think
Matthew Frankel, The Motley Fool - Motley Fool - Sun Nov 15, 2:18PM CST
Photo: Flickr user ITU Pictures. There have been several media reports about younger investors who are scared to put their money in stocks, but there's some evidence to suggest otherwise. Here's what millennials are doing in their portfolios, and...
NFLX: 103.65 (-5.27), TSLA: 207.19 (-5.75), JNJ: 99.88 (-0.39), AMZN: 642.35 (-23.25), FB: 103.95 (-4.07), PG: 73.96 (-0.70), O: 47.44 (unch), AMTD: 35.70 (-0.34)
The Best Stocks in Conglomerates
Reuben Gregg Brewer, The Motley Fool - Motley Fool - Sun Nov 15, 9:15AM CST
Conglomerates go in and out of favor, with periods of mergers juxtaposed against periods of divestitures. However, there are a few names in the space that seem to make the idea of putting often disparate businesses under one roof work. The biggest...
JNJ: 99.88 (-0.39), GE: 30.28 (+0.12)
5 Things Johnson & Johnson Wants You to Know
Sean Williams, The Motley Fool - Motley Fool - Fri Nov 13, 2:38PM CST
CEO Alex Gorsky. Image source: Johnson & Johnson. It's been a few weeks since healthcare conglomerate Johnson & Johnson reported its third-quarter earnings results, handily surpassing Wall Street's profit estimates once again, and...
JNJ: 99.88 (-0.39)
Johnson & Johnson Consumer Inc.'s Care to Recycle Program and Scholastic Announce Winners of National Recycling Contest: PETE's Bathroom Bin Challenge
PR Newswire - Fri Nov 13, 8:00AM CST
In celebration of America Recycles Dayi on November 15, 2015, Johnson & Johnson Consumer Inc.'s Care to Recycle® program and Scholastic today announced the winners of PETE's Bathroom Bin Challenge, a nationwide contest conducted to teach kids the importance of recycling throughout the house, including the bathroom.
JNJ: 99.88 (-0.39)
6 'Defensive-Growth' Blue-Chip Stocks for the New Year
at The Street - Thu Nov 12, 11:46AM CST
If you're concerned about market volatility but refuse to sit on the sidelines, these six growth stock stalwarts should provide both safety and capital appreciation for 2016.
JNJ: 99.88 (-0.39), WHR: 151.07 (-4.43), UTX: 96.48 (-2.74), FLT: 146.82 (-3.81), BA: 142.59 (+0.05)
Johnson & Johnson Becomes #10 Most Shorted Dow Stock, Replacing American Express
MarketNewsVideo.com - Thu Nov 12, 8:44AM CST
The most recent short interest data has been released by the NASDAQ for the 10/30/2015 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Dow Jones Industrial Average by...
JNJ: 99.88 (-0.39)
Covered Call Alerts For Apple, SPDR Gold Trust, Chevron, Johnson & Johnson and SanDisk Released By InvestorsObserver
PR Newswire - Thu Nov 12, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for AAPL, GLD, CVX, JNJ and SNDK.
JNJ: 99.88 (-0.39), GLD: 103.56 (-0.29), CVX: 88.68 (-1.18), AAPL: 112.34 (-3.38), SNDK: 73.90 (-0.52)
Boston Scientific Slides On Proposed Device Coverage
at Investor's Business Daily - Wed Nov 11, 4:25PM CST
Medical-device giant Boston Scientific (BSX) fell 4.2% Wednesday after the U.S. government proposed limiting coverage of its new heart implant. Late Tuesday, the Centers for Medicare and Medicaid Services (CMS) issued the proposed guidelines covering...
BSX: 17.51 (-0.23), JNJ: 99.88 (-0.39), PFE: 33.27 (-0.12)
Next Resistance Level for Johnson & Johnson (JNJ) is $102.38
Comtex SmarTrend(R) - Wed Nov 11, 9:03AM CST
Shares of Johnson & Johnson (NYSE:JNJ) have bullishly opened above the pivot of $101.30 today and have reached the first resistance level of $101.91. Investors may be interested in a cross of the next upside pivot targets of $102.38 and $103.46.
JNJ: 99.88 (-0.39)
Pelvic Mesh Lawsuit Funding Firm, Fair Rate Funding, Reports an Overturned Mesh Verdict in Baptiste v. J&J
PR Newswire - Wed Nov 11, 8:00AM CST
Fair Rate Funding, a leader in pelvic mesh lawsuit funding, reports that a recent trial court jury verdict in favor of plaintiff, Linda Batiste against defendant, Ethicon and their parent company, Johnson and Johnson was reversed in Texas. The Batiste case was the first mesh case to go to trial in that state. The jury decided Johnson & Johnson's (J&J) TVT-Obturator (TVT-O), made by Ethicon, a division of J&J, was defective in its design and awarded Ms. Batiste $1.2 million.
JNJ: 99.88 (-0.39)
$1.75 Million Jury Verdict Awarded in Risperdal Antipsychotic Lawsuit; Sheller, P.C. Plaintiff Alleged Drug Caused Female-Like Breast Development
PR Newswire - Wed Nov 11, 8:00AM CST
A Philadelphia jury has awarded $1.75 million to a young man who claimed his taking the antipsychotic drug Risperdal caused him to grow female-like breasts.
JNJ: 99.88 (-0.39)
Should Healthcare Dividend Hunters Target AbbVie or Johnson & Johnson?
Cory Renauer, The Motley Fool - Motley Fool - Wed Nov 11, 7:01AM CST
For those seeking a steady source of income in the form of dividends, pharmaceutical heavyweight AbbVie and healthcare conglomerate Johnson & Johnson both have plenty to offer. Since its spinoff from parent company Abbott Laboratories at...
JNJ: 99.88 (-0.39), ABBV: 59.86 (-0.37)
'Mad Money' Lightning Round: Northrop Grumman, Lockheed Martin Both Terrific
at The Street - Wed Nov 11, 5:00AM CST
Cramer likes Johnson & Johnson, Stryker and Edwards Lifesciences, while avoiding all Chinese stocks.
ABMD: 80.12 (+0.76), LMT: 213.16 (-0.42), NOC: 178.82 (-1.49), EW: 153.27 (+0.32), UL: 42.00 (-0.60), DYAX: 34.42 (+0.03), JNJ: 99.88 (-0.39), BIDU: 193.95 (-4.19), GS: 190.39 (-2.38), GWPH: 82.71 (+1.69), MRK: 53.03 (unch), CHL: 57.48 (-1.67), SYK: 95.63 (+0.02)
Jim Cramer's 'Mad Money' Recap: Winners Remain When Rates Rise
at The Street - Tue Nov 10, 6:39PM CST
When interest rates begin to rise, it may be harder to find winners, Cramer said. But only a pessimist would stop looking.
ABMD: 80.12 (+0.76), AMZN: 642.35 (-23.25), LMT: 213.16 (-0.42), NOC: 178.82 (-1.49), FB: 103.95 (-4.07), EW: 153.27 (+0.32), STZ: 132.20 (-1.18), UL: 42.00 (-0.60), DYAX: 34.42 (+0.03), NFLX: 103.65 (-5.27), WWAV: 40.56 (-0.93), JNJ: 99.88 (-0.39), BIDU: 193.95 (-4.19), GS: 190.39 (-2.38), GWPH: 82.71 (+1.69), CHL: 57.48 (-1.67), MRK: 53.03 (unch), MCD: 109.97 (-2.14), GOOGL: 740.07 (-16.46), XLF: 23.92 (-0.20), AAPL: 112.34 (-3.38), SYK: 95.63 (+0.02), PII: 106.91 (-3.34)
Stock Screen Results Can Say A Lot About The Market
at Investor's Business Daily - Tue Nov 10, 4:27PM CST
No single stock screen will be the best in every uptrend. Different uptrends reward different kinds of stocks, and the screens reflect that reality. For example, during the last bear market, the aggressive and growthy complexion of the IBD 50 (then...
JNJ: 99.88 (-0.39), CPB: 47.97 (-0.33), PG: 73.96 (-0.70), EE: 38.90 (-0.38), SBNY: 151.31 (-1.46), OZRK: 52.32 (-0.54)
3 Midsize Drug Stocks Moving On Q3 Reports
at Investor's Business Daily - Tue Nov 10, 12:34PM CST
Midcap drugmakers Jazz Pharmaceuticals, Halozyme Therapeutics and Depomed were moving in the stock market Tuesday after they reported Q3 earnings late Monday, rounding out a mixed earnings season for the beleaguered sector. Jazz Pharmaceuticals...
JNJ: 99.88 (-0.39), HALO: 15.41 (+0.10), JAZZ: 134.77 (+0.76), HZNP: 17.99 (+0.38), DEPO: 18.69 (-0.99), CELG: 107.49 (-1.53)
Global Market Study on Neurosurgical Products 2015-2020: Market is Anticipated to Grow to US$7,756.2 Mn by 2022
M2 - Tue Nov 10, 8:19AM CST
Research and Markets (http://www.researchandmarkets.com/research/6q83k8/global_market) has announced the addition of the "Global Market Study on Neurosurgical Products: Asia Pacific to Witness Highest Growth by 2022" report to their offering. The neurosurgical products market is anticipated to grow from an estimated US$3,685.8 Mn by the end of 2015 to US$7,756.2 Mn by 2022at a CAGR of 11.2% during the forecast period. The global neurosurgical products market is witnessing significant growth due to growing geriatric population. Moreover, increasing the incidence of brain tumors, growing government funding, and raising awareness about neurosurgical disorders are also driving the growth of the market. Furthermore, growing demand for minimally invasive surgeries is expected to create growth opportunities for the neurosurgical products market. However, stringent regulatory requirements, long approval times for new neurosurgical products, and availability of alternative treatment for neurosurgical diseases inhibit the growth of the market. North America is projected to be the largest market for neurosurgical products, with an aneurysm being the most prevalent neurosurgical condition, and embolization products being the most preferred neurosurgical product by the end of 2015. Asia Pacific is expected to be the fastest-growing region in terms of revenue while stereotactic radiosurgery is projected to be the fastest-growing neurosurgical product type segment over the forecast period. Aneurysms are abnormal widening or bulging of parts of blood vessels due to weakening of the wall of the blood vessel.The global aneurysms segment is expected to grow from an estimated US$1,328.8 Mn by the end of2015 to US$2,866.1 Mn by 2022 at a CAGR of 11.6% during the forecast period. Key Topics Covered: Chapter 1 Preface Chapter 2 Market Synopsis Chapter 3 Porter's Five Forces Analysis Chapter 4 Industry Overview Chapter 5 Global Market Size and Forecast Chapter 6 Market Size and Forecast by Condition Chapter 7 Market Size and Forecast by Procedure Chapter 8 Market Size and Forecast by Product Type Chapter 9 Market Size and Forecast by Geography Chapter 10 Competitive Scenario Chapter 11 Company Profiles - B. Braun Melsungen AG - Elekta AB - Integra LifeSciences Holdings Corporation - Johnson & Johnson Services, Inc. - KARL STORZ GmbH & Co. KG. - Medtronic plc - Penumbra, Inc. - Stryker Corporation - Terumo Corporation - Varian Medical Systems, Inc. For more information visit http://www.researchandmarkets.com/research/6q...bal_market
JNJ: 99.88 (-0.39), VAR: 78.47 (-0.03), MDT: 74.46 (+0.25), IARTV: 65.00 (-37.45), PEN: 49.80 (+9.53), SYK: 95.63 (+0.02)
Biological Dynamics Appoints Paul Billings, MD, PhD, to Board of Directors
Business Wire - Tue Nov 10, 8:00AM CST
Biological Dynamics Inc., a privately held molecular diagnostics company and a pioneer in the field of Alternating Current Electrokinetics (ACE) - based diagnostics, announces the appointment of Paul Richard Billings, MD, PhD, FACP, FACMG, to the Company's Board of Directors. His addition increases Board membership to four directors.
JNJ: 99.88 (-0.39)
Johnson & Johnson Inc. Named One of Canada's Top 100 Employers
CNW Group - Tue Nov 10, 6:45AM CST
Award recognizes company's commitment to building the country's healthiest workforce
JNJ: 99.88 (-0.39)
Global Markets for Arthroscopy, Bronchoscopy, ENT Endoscopy, Neuroendoscopy, and Spinal Endoscopy in 2015
M2 - Tue Nov 10, 3:35AM CST
Research and Markets (http://www.researchandmarkets.com/research/b9nd7c/global_markets) has announced the addition of the "Global Markets for Arthroscopy, Bronchoscopy, ENT Endoscopy, Neuroendoscopy, and Spinal Endoscopy in 2015" report to their offering. Robust growth is expected for sales of minimally invasive surgical products through 2020 The market, which was valued at $8.4 billion in 2014 and includes arthroscopes, bronchoscopes, endoscopes, instrumentation, access devices, and related products is benefiting from the adoption of new devices and techniques that expand the range of surgical caseloads; patient and clinical preference for less-invasive surgical methods; and rising access to advanced technologies in emerging markets. This analysis-which provides detailed forecasts for product segments, clinical caseloads, and global regions-explores the key forces shaping the market, examines competitive market shares, and provides detailed quantitative segmentation for endoscopic procedures and devices. Critical Issues Covered in this Report: - The competitive landscape for these devices in the U.S. and international markets; - Quantitative factors including revenues, procedures, and product sales; and - Surgical volumes, caseloads, and other key infrastructure and market metrics. Key Topics Covered: 1. Executive Summary 1.1 The United States 1.2 Europe 1.3 Asia-Pacific And The Rest Of The World 1.4 Competitive Analysis 2. Products Used In Arthroscopy, Bronchoscopy, Ent Endoscopy, Neuroendoscopy, And Spinal Endoscopy 2.1 Endoscopes 2.1.1 Arthroscopes 2.1.2 Bronchoscopes 2.1.3 Ent Endoscopes 2.1.4 Neuroendoscopes 2.1.5 Spinal Endoscopes 2.1.6 Other Products 2.2 Products & Suppliers 3. Arthroscopy, Bronchoscopy, Ent Endoscopy, Neuroendoscopy, And Spinal Endoscopy: Global Market Analysis 3.1 The United States 3.2 Europe 3.3 Asia-Pacific And The Rest Of The World 4. Companies Covered - Arthrex - Asap Endoscopic Products - B. Braun - Boston Scientific - Canada Endoscope Corporation - Cogentix Medical - Conmed - Covidien - Fujifilm - Integrated Endoscopy - Johnson & Johnson - Joimax - Karl Storz - Medtronic - Myelotec - Olympus - Osi - Richard Wolf - Richards - Rz Medizintechnik - Schoelly Fiberoptic - Smith & Nephew - Spine View - Stryker - Trice Medical - Visionscope Technologies - Xomed For more information visit http://www.researchandmarkets.com/research/b9...al_markets
BSX: 17.51 (-0.23), SNN: 32.74 (-0.11), JNJ: 99.88 (-0.39), MDT: 74.46 (+0.25), CGNT: 1.59 (+0.05)
Millennials Are Investing More in Stocks Than You May Think
Matthew Frankel, The Motley Fool - Motley Fool - Sun Nov 15, 2:18PM CST
Photo: Flickr user ITU Pictures. There have been several media reports about younger investors who are scared to put their money in stocks, but there's some evidence to suggest otherwise. Here's what millennials are doing in their portfolios, and...
NFLX: 103.65 (-5.27), TSLA: 207.19 (-5.75), JNJ: 99.88 (-0.39), AMZN: 642.35 (-23.25), FB: 103.95 (-4.07), PG: 73.96 (-0.70), O: 47.44 (unch), AMTD: 35.70 (-0.34)
The Best Stocks in Conglomerates
Reuben Gregg Brewer, The Motley Fool - Motley Fool - Sun Nov 15, 9:15AM CST
Conglomerates go in and out of favor, with periods of mergers juxtaposed against periods of divestitures. However, there are a few names in the space that seem to make the idea of putting often disparate businesses under one roof work. The biggest...
JNJ: 99.88 (-0.39), GE: 30.28 (+0.12)
5 Things Johnson & Johnson Wants You to Know
Sean Williams, The Motley Fool - Motley Fool - Fri Nov 13, 2:38PM CST
CEO Alex Gorsky. Image source: Johnson & Johnson. It's been a few weeks since healthcare conglomerate Johnson & Johnson reported its third-quarter earnings results, handily surpassing Wall Street's profit estimates once again, and...
JNJ: 99.88 (-0.39)
Johnson & Johnson Consumer Inc.'s Care to Recycle Program and Scholastic Announce Winners of National Recycling Contest: PETE's Bathroom Bin Challenge
PR Newswire - Fri Nov 13, 8:00AM CST
In celebration of America Recycles Dayi on November 15, 2015, Johnson & Johnson Consumer Inc.'s Care to Recycle® program and Scholastic today announced the winners of PETE's Bathroom Bin Challenge, a nationwide contest conducted to teach kids the importance of recycling throughout the house, including the bathroom.
JNJ: 99.88 (-0.39)
6 'Defensive-Growth' Blue-Chip Stocks for the New Year
at The Street - Thu Nov 12, 11:46AM CST
If you're concerned about market volatility but refuse to sit on the sidelines, these six growth stock stalwarts should provide both safety and capital appreciation for 2016.
JNJ: 99.88 (-0.39), WHR: 151.07 (-4.43), UTX: 96.48 (-2.74), FLT: 146.82 (-3.81), BA: 142.59 (+0.05)
Johnson & Johnson Becomes #10 Most Shorted Dow Stock, Replacing American Express
MarketNewsVideo.com - Thu Nov 12, 8:44AM CST
The most recent short interest data has been released by the NASDAQ for the 10/30/2015 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Dow Jones Industrial Average by...
JNJ: 99.88 (-0.39)
Covered Call Alerts For Apple, SPDR Gold Trust, Chevron, Johnson & Johnson and SanDisk Released By InvestorsObserver
PR Newswire - Thu Nov 12, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for AAPL, GLD, CVX, JNJ and SNDK.
JNJ: 99.88 (-0.39), GLD: 103.56 (-0.29), CVX: 88.68 (-1.18), AAPL: 112.34 (-3.38), SNDK: 73.90 (-0.52)
Boston Scientific Slides On Proposed Device Coverage
at Investor's Business Daily - Wed Nov 11, 4:25PM CST
Medical-device giant Boston Scientific (BSX) fell 4.2% Wednesday after the U.S. government proposed limiting coverage of its new heart implant. Late Tuesday, the Centers for Medicare and Medicaid Services (CMS) issued the proposed guidelines covering...
BSX: 17.51 (-0.23), JNJ: 99.88 (-0.39), PFE: 33.27 (-0.12)
Next Resistance Level for Johnson & Johnson (JNJ) is $102.38
Comtex SmarTrend(R) - Wed Nov 11, 9:03AM CST
Shares of Johnson & Johnson (NYSE:JNJ) have bullishly opened above the pivot of $101.30 today and have reached the first resistance level of $101.91. Investors may be interested in a cross of the next upside pivot targets of $102.38 and $103.46.
JNJ: 99.88 (-0.39)
Pelvic Mesh Lawsuit Funding Firm, Fair Rate Funding, Reports an Overturned Mesh Verdict in Baptiste v. J&J
PR Newswire - Wed Nov 11, 8:00AM CST
Fair Rate Funding, a leader in pelvic mesh lawsuit funding, reports that a recent trial court jury verdict in favor of plaintiff, Linda Batiste against defendant, Ethicon and their parent company, Johnson and Johnson was reversed in Texas. The Batiste case was the first mesh case to go to trial in that state. The jury decided Johnson & Johnson's (J&J) TVT-Obturator (TVT-O), made by Ethicon, a division of J&J, was defective in its design and awarded Ms. Batiste $1.2 million.
JNJ: 99.88 (-0.39)
$1.75 Million Jury Verdict Awarded in Risperdal Antipsychotic Lawsuit; Sheller, P.C. Plaintiff Alleged Drug Caused Female-Like Breast Development
PR Newswire - Wed Nov 11, 8:00AM CST
A Philadelphia jury has awarded $1.75 million to a young man who claimed his taking the antipsychotic drug Risperdal caused him to grow female-like breasts.
JNJ: 99.88 (-0.39)
Should Healthcare Dividend Hunters Target AbbVie or Johnson & Johnson?
Cory Renauer, The Motley Fool - Motley Fool - Wed Nov 11, 7:01AM CST
For those seeking a steady source of income in the form of dividends, pharmaceutical heavyweight AbbVie and healthcare conglomerate Johnson & Johnson both have plenty to offer. Since its spinoff from parent company Abbott Laboratories at...
JNJ: 99.88 (-0.39), ABBV: 59.86 (-0.37)
'Mad Money' Lightning Round: Northrop Grumman, Lockheed Martin Both Terrific
at The Street - Wed Nov 11, 5:00AM CST
Cramer likes Johnson & Johnson, Stryker and Edwards Lifesciences, while avoiding all Chinese stocks.
ABMD: 80.12 (+0.76), LMT: 213.16 (-0.42), NOC: 178.82 (-1.49), EW: 153.27 (+0.32), UL: 42.00 (-0.60), DYAX: 34.42 (+0.03), JNJ: 99.88 (-0.39), BIDU: 193.95 (-4.19), GS: 190.39 (-2.38), GWPH: 82.71 (+1.69), MRK: 53.03 (unch), CHL: 57.48 (-1.67), SYK: 95.63 (+0.02)
Jim Cramer's 'Mad Money' Recap: Winners Remain When Rates Rise
at The Street - Tue Nov 10, 6:39PM CST
When interest rates begin to rise, it may be harder to find winners, Cramer said. But only a pessimist would stop looking.
ABMD: 80.12 (+0.76), AMZN: 642.35 (-23.25), LMT: 213.16 (-0.42), NOC: 178.82 (-1.49), FB: 103.95 (-4.07), EW: 153.27 (+0.32), STZ: 132.20 (-1.18), UL: 42.00 (-0.60), DYAX: 34.42 (+0.03), NFLX: 103.65 (-5.27), WWAV: 40.56 (-0.93), JNJ: 99.88 (-0.39), BIDU: 193.95 (-4.19), GS: 190.39 (-2.38), GWPH: 82.71 (+1.69), CHL: 57.48 (-1.67), MRK: 53.03 (unch), MCD: 109.97 (-2.14), GOOGL: 740.07 (-16.46), XLF: 23.92 (-0.20), AAPL: 112.34 (-3.38), SYK: 95.63 (+0.02), PII: 106.91 (-3.34)
Stock Screen Results Can Say A Lot About The Market
at Investor's Business Daily - Tue Nov 10, 4:27PM CST
No single stock screen will be the best in every uptrend. Different uptrends reward different kinds of stocks, and the screens reflect that reality. For example, during the last bear market, the aggressive and growthy complexion of the IBD 50 (then...
JNJ: 99.88 (-0.39), CPB: 47.97 (-0.33), PG: 73.96 (-0.70), EE: 38.90 (-0.38), SBNY: 151.31 (-1.46), OZRK: 52.32 (-0.54)
3 Midsize Drug Stocks Moving On Q3 Reports
at Investor's Business Daily - Tue Nov 10, 12:34PM CST
Midcap drugmakers Jazz Pharmaceuticals, Halozyme Therapeutics and Depomed were moving in the stock market Tuesday after they reported Q3 earnings late Monday, rounding out a mixed earnings season for the beleaguered sector. Jazz Pharmaceuticals...
JNJ: 99.88 (-0.39), HALO: 15.41 (+0.10), JAZZ: 134.77 (+0.76), HZNP: 17.99 (+0.38), DEPO: 18.69 (-0.99), CELG: 107.49 (-1.53)
Global Market Study on Neurosurgical Products 2015-2020: Market is Anticipated to Grow to US$7,756.2 Mn by 2022
M2 - Tue Nov 10, 8:19AM CST
Research and Markets (http://www.researchandmarkets.com/research/6q83k8/global_market) has announced the addition of the "Global Market Study on Neurosurgical Products: Asia Pacific to Witness Highest Growth by 2022" report to their offering. The neurosurgical products market is anticipated to grow from an estimated US$3,685.8 Mn by the end of 2015 to US$7,756.2 Mn by 2022at a CAGR of 11.2% during the forecast period. The global neurosurgical products market is witnessing significant growth due to growing geriatric population. Moreover, increasing the incidence of brain tumors, growing government funding, and raising awareness about neurosurgical disorders are also driving the growth of the market. Furthermore, growing demand for minimally invasive surgeries is expected to create growth opportunities for the neurosurgical products market. However, stringent regulatory requirements, long approval times for new neurosurgical products, and availability of alternative treatment for neurosurgical diseases inhibit the growth of the market. North America is projected to be the largest market for neurosurgical products, with an aneurysm being the most prevalent neurosurgical condition, and embolization products being the most preferred neurosurgical product by the end of 2015. Asia Pacific is expected to be the fastest-growing region in terms of revenue while stereotactic radiosurgery is projected to be the fastest-growing neurosurgical product type segment over the forecast period. Aneurysms are abnormal widening or bulging of parts of blood vessels due to weakening of the wall of the blood vessel.The global aneurysms segment is expected to grow from an estimated US$1,328.8 Mn by the end of2015 to US$2,866.1 Mn by 2022 at a CAGR of 11.6% during the forecast period. Key Topics Covered: Chapter 1 Preface Chapter 2 Market Synopsis Chapter 3 Porter's Five Forces Analysis Chapter 4 Industry Overview Chapter 5 Global Market Size and Forecast Chapter 6 Market Size and Forecast by Condition Chapter 7 Market Size and Forecast by Procedure Chapter 8 Market Size and Forecast by Product Type Chapter 9 Market Size and Forecast by Geography Chapter 10 Competitive Scenario Chapter 11 Company Profiles - B. Braun Melsungen AG - Elekta AB - Integra LifeSciences Holdings Corporation - Johnson & Johnson Services, Inc. - KARL STORZ GmbH & Co. KG. - Medtronic plc - Penumbra, Inc. - Stryker Corporation - Terumo Corporation - Varian Medical Systems, Inc. For more information visit http://www.researchandmarkets.com/research/6q...bal_market
JNJ: 99.88 (-0.39), VAR: 78.47 (-0.03), MDT: 74.46 (+0.25), IARTV: 65.00 (-37.45), PEN: 49.80 (+9.53), SYK: 95.63 (+0.02)
Biological Dynamics Appoints Paul Billings, MD, PhD, to Board of Directors
Business Wire - Tue Nov 10, 8:00AM CST
Biological Dynamics Inc., a privately held molecular diagnostics company and a pioneer in the field of Alternating Current Electrokinetics (ACE) - based diagnostics, announces the appointment of Paul Richard Billings, MD, PhD, FACP, FACMG, to the Company's Board of Directors. His addition increases Board membership to four directors.
JNJ: 99.88 (-0.39)
Johnson & Johnson Inc. Named One of Canada's Top 100 Employers
CNW Group - Tue Nov 10, 6:45AM CST
Award recognizes company's commitment to building the country's healthiest workforce
JNJ: 99.88 (-0.39)
Global Markets for Arthroscopy, Bronchoscopy, ENT Endoscopy, Neuroendoscopy, and Spinal Endoscopy in 2015
M2 - Tue Nov 10, 3:35AM CST
Research and Markets (http://www.researchandmarkets.com/research/b9nd7c/global_markets) has announced the addition of the "Global Markets for Arthroscopy, Bronchoscopy, ENT Endoscopy, Neuroendoscopy, and Spinal Endoscopy in 2015" report to their offering. Robust growth is expected for sales of minimally invasive surgical products through 2020 The market, which was valued at $8.4 billion in 2014 and includes arthroscopes, bronchoscopes, endoscopes, instrumentation, access devices, and related products is benefiting from the adoption of new devices and techniques that expand the range of surgical caseloads; patient and clinical preference for less-invasive surgical methods; and rising access to advanced technologies in emerging markets. This analysis-which provides detailed forecasts for product segments, clinical caseloads, and global regions-explores the key forces shaping the market, examines competitive market shares, and provides detailed quantitative segmentation for endoscopic procedures and devices. Critical Issues Covered in this Report: - The competitive landscape for these devices in the U.S. and international markets; - Quantitative factors including revenues, procedures, and product sales; and - Surgical volumes, caseloads, and other key infrastructure and market metrics. Key Topics Covered: 1. Executive Summary 1.1 The United States 1.2 Europe 1.3 Asia-Pacific And The Rest Of The World 1.4 Competitive Analysis 2. Products Used In Arthroscopy, Bronchoscopy, Ent Endoscopy, Neuroendoscopy, And Spinal Endoscopy 2.1 Endoscopes 2.1.1 Arthroscopes 2.1.2 Bronchoscopes 2.1.3 Ent Endoscopes 2.1.4 Neuroendoscopes 2.1.5 Spinal Endoscopes 2.1.6 Other Products 2.2 Products & Suppliers 3. Arthroscopy, Bronchoscopy, Ent Endoscopy, Neuroendoscopy, And Spinal Endoscopy: Global Market Analysis 3.1 The United States 3.2 Europe 3.3 Asia-Pacific And The Rest Of The World 4. Companies Covered - Arthrex - Asap Endoscopic Products - B. Braun - Boston Scientific - Canada Endoscope Corporation - Cogentix Medical - Conmed - Covidien - Fujifilm - Integrated Endoscopy - Johnson & Johnson - Joimax - Karl Storz - Medtronic - Myelotec - Olympus - Osi - Richard Wolf - Richards - Rz Medizintechnik - Schoelly Fiberoptic - Smith & Nephew - Spine View - Stryker - Trice Medical - Visionscope Technologies - Xomed For more information visit http://www.researchandmarkets.com/research/b9...al_markets
BSX: 17.51 (-0.23), SNN: 32.74 (-0.11), JNJ: 99.88 (-0.39), MDT: 74.46 (+0.25), CGNT: 1.59 (+0.05)
